Fouad Namouni Sells 3,633 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded up $0.54 during trading hours on Friday, hitting $88.61. The company’s stock had a trading volume of 310,070 shares, compared to its average volume of 699,484. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71. Blueprint Medicines Co. has a 12-month low of $43.89 and a 12-month high of $121.90. The business has a 50 day moving average price of $93.06 and a two-hundred day moving average price of $98.95. The company has a market cap of $5.55 billion, a PE ratio of -18.40 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. The business had revenue of $138.20 million during the quarter, compared to the consensus estimate of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The firm’s revenue for the quarter was up 139.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.19) EPS. Analysts expect that Blueprint Medicines Co. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. Oppenheimer upped their price objective on Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, July 8th. Barclays raised their target price on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. Guggenheim upped their price target on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, JMP Securities reissued a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a report on Friday, June 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $120.00.

Institutional Trading of Blueprint Medicines

Several hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its holdings in shares of Blueprint Medicines by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 135,969 shares of the biotechnology company’s stock worth $12,542,000 after purchasing an additional 4,746 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Blueprint Medicines by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after acquiring an additional 147,827 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Blueprint Medicines during the 4th quarter valued at approximately $9,768,000. Diversified Trust Co boosted its position in shares of Blueprint Medicines by 3.6% during the 1st quarter. Diversified Trust Co now owns 14,472 shares of the biotechnology company’s stock valued at $1,373,000 after acquiring an additional 498 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Blueprint Medicines in the first quarter valued at $218,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.